Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns
September 28th 2023Cases of COVID-19, RSV, and influenza are expected to rise this fall and winter season; yet, the number of people who plan on getting the vaccines for each of the infections remains low, according to the NFID announcement today.
Understanding the Environmental Spread of Emerging Pathogens
September 19th 2023The AHE Exchange Conference in Dallas focused on emerging pathogens and the role of environmental services. Doe Kley, MPH, RN, T-CHEST, LTC-CIP, CIC, discusses her and other exceptional presentations with Infection Control Today.
Eagle Pharmaceuticals Announces Phase 2 Study for Anti-Toxin Drug Candidate for SCABP
August 21st 2023Eagle Pharmaceuticals randomized its first patient in the Phase 2 study of CAL02, a safe and promising anti-toxin drug that treats severe community-acquired bacterial pneumonia without contributing to antibiotic resistance.
FDA Approves RSV Drug for Children Up to 24 Months
July 17th 2023AstraZeneca's new drug, a monoclonal antibody, was given FDA approval after the Antimicrobial Drugs Advisory Committee (AMDAC) to the FDA voted in June to recommend the approval of nirsevimab (Beyfortus) for the prevention of respiratory syncytial virus (RSV) disease in infants.
Opinion: Post Pandemic Strategies Are Inadequate To Assure Public Safety
July 13th 2023In his analysis, Kevin Kavanagh, MD, explores the measures taken by the infectious disease sector in response to the pandemic, pointing out both effective and ineffective approaches. He also discusses how the pandemic has affected the treatment of other infectious diseases.
Candida auris: Using Public Health Messaging to Address Prevention
March 31st 2023Despite the recent CDC warning and frightening media coverage, understanding which patients are at a higher risk of Candida auris is important too. The lead author of the recent CDC's study spoke to ICT's sister brand for further insights on the threat.